A Florida man has filed a Dupixent lawsuit alleging that the atopic dermatitis treatment caused him to develop a rare form of blood cancer. Giovanni Fraioli filed his lawsuit in the U.S. District Court for the Southern District of Florida on January 30, 2026, claiming that the drug’s manufacturers, Regeneron Pharmaceuticals Inc., Sanofi-Aventis U.S. LLC, and Genzyme Corporation, failed to adequately warn healthcare providers and patients about potential cancer risks allegedly associated with the medication.
Dupixent and Its Alleged Cancer Risks
Dupixent (dupilumab) received FDA approval in 2017 for the treatment of atopic dermatitis, a common form of eczema characterized by itchy, inflamed skin. Since then, the FDA has expanded its approved uses to include asthma, chronic obstructive pulmonary disease (COPD), and other inflammatory conditions affecting the respiratory system and skin. The medication works by targeting specific pathways in the immune system to reduce inflammation.
Despite being marketed as safe and effective, concerns have emerged recently regarding a potential connection between Dupixent and T-cell lymphoma, particularly cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). These rare cancers affect white blood cells, which play crucial roles in the body’s immune function.
What Does the Scientific Research Say?
Medical research suggests that patients treated with Dupixent may face a significantly elevated risk of developing CTCL compared to those not using the medication. According to studies published in dermatological journals, Dupixent users with eczema may have more than four times the relative risk of developing this rare cancer compared to non-users.
Fraioli’s Dupixent lawsuit highlights that the drug’s warning label lacks specific information about these potential cancer risks, which allegedly prevented patients and healthcare providers from making fully informed decisions about their treatment.
Details of the Latest Dupixent Cancer Lawsuit
According to court documents, Giovanni Fraioli began using Dupixent in December 2019 to treat his atopic dermatitis. Approximately two years later, he received a diagnosis of Mycosis Fungoides, a form of cutaneous T-cell lymphoma. Despite this diagnosis, Fraioli continued using Dupixent until October 2021, allegedly unaware of any potential connection between the medication and his cancer.
Fraioli’s Dupixent lawsuit states that he has endured extensive cancer treatments, including chemotherapy and phototherapy. His phototherapy treatments have reportedly continued twice weekly for more than three years, representing a significant burden on his quality of life and financial resources.
Dupixent Manufacturers Allegedly Aware of Cancer Link
Fraioli further asserts that the manufacturers received reports of CTCL in Dupixent users as early as March 2018, just one year after the drug’s approval. By the end of 2018, the companies had allegedly received 15 spontaneous reports of CTCL diagnoses among patients using Dupixent. The lawsuit claims that by the end of 2024, more than 200 reports of CTCL had been linked to Dupixent use.
The complaint includes several legal claims against the manufacturers, including:
- Failure to warn about known risks
- Negligence in product development and monitoring
- Fraudulent misrepresentation of safety data
- Negligent misrepresentation regarding product risks
Fraioli is seeking both compensatory damages for his medical expenses, pain and suffering, and lost income, as well as punitive damages against the manufacturers.
Broader Implications for Dupixent Users
More than one million people worldwide have been treated with Dupixent since its approval. For many patients with severe atopic dermatitis or asthma, Dupixent has provided significant symptom relief when other treatments failed. However, the emerging litigation raises important questions about risk disclosure and patient safety. Healthcare providers and patients rely on accurate, comprehensive information about potential medication risks to make informed treatment decisions. When manufacturers allegedly withhold or downplay potential risks, patients may be exposed to side effects they may not have accepted had they been fully informed.
The Future of Dupixent for Atopic Dermatitis Treatment
Giovanni Fraioli’s lawsuit represents one of a growing number of legal claims against the manufacturers of Dupixent. These lawsuits generally allege that Regeneron Pharmaceuticals Inc., Sanofi-Aventis U.S. LLC, and Genzyme Corporation prioritized profits over patient safety by failing to adequately research potential health risks or properly warn about dangers they knew or should have known about.
In the meantime, independent researchers continue to investigate the potential relationship between Dupixent and an increased risk of cancer. Future Dupixent studies may provide clearer insights into which patients might face elevated risks and whether specific monitoring protocols could help identify cancer earlier in those using the medication.
For current Dupixent users, medical experts recommend maintaining regular follow-up appointments with healthcare providers and promptly reporting any new or worsening symptoms. Patients should not discontinue prescribed medications without consulting their healthcare providers, as the benefits of treatment may still outweigh potential risks for many individuals.
Dupixent Lawsuit Information
GA Woman Files Dupixent Lawsuit Alleging Link to Cancer Diagnosis, Leading Justice
